Rotondo, Caitlyn Michelle2014-12-042014-12-042014-12-04https://laurentian.scholaris.ca/handle/10219/2291Metallo-β-lactamases (MBLs) are major contributors to bacterial antibiotic resistance due to their ability to cleave most β-lactam antibiotics. At the present time there are no clinically approved inhibitors of MBLs. However, previous preliminary studies have demonstrated that cationic peptides have the ability to inhibit these enzymes. Herein, more thorough investigations into the structure-activity relationship between two MBLs, VIM-2 and IMP-1, and cationic peptides are described, demonstrating that the inhibitory potency of these peptides increased with the number of arginine residues (IC50 of 10 nM for the most potent VIM-2 inhibitor). The degree of inhibition also varied depending on the β-lactam substrate and the MBL employed. Furthermore, steady-state and stopped-flow spectrophotometric studies demonstrated that the inhibition mediated by these peptides followed a complex mode of inhibition. In addition, results from spectroscopic studies (including UV-Vis, tryptophan fluorescence and dynamic light scattering) showed that the inhibition of MBLs by cationic peptides results in partially reversible peptide-influenced MBL aggregation. The better understanding of the relationship between these peptides and MBLs may lead to the development of novel MBL inhibitors suitable for clinical use.enBacteriaAntibiotic Resistanceβ-LactamasesBacteria, AntMetallo-β-lactamasesThesis